NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
B2017-023-01
Phase 1 mab active
Quick answer
NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） for Bone Sarcoma is a Phase 1 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PRECISION BIOSCIENCES INC
- Indication
- Bone Sarcoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active